Related Experiment Video
Updated: Jan 15, 2026
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
EC2-mutant Mycoplasma pneumoniae in pediatric ITP: severe hemorrhage with accelerated platelet recovery
Jiaqian Wan1, Xi Lin2, Jingyao Ma3
1Pediatric Department Yunnan Baoshan People's Hospital, Baoshan, Yunnan, China.
Abstract:
Background evidence indicates that the macrolide-resistant EC2 mutant of Mycoplasma pneumoniae (MP) emerged as the predominant strain during the 2023-2024 epidemic, being associated with immune-mediated complications (e.g., severe immune thrombocytopenia [ITP]), whose clinical characteristics and prognosis remain undefined. This study aimed to compare the severity of bleeding, treatment response and long-term prognosis in children with newly diagnosed severe ITP and non-MP-associated ITP with MP-related mutations during the epidemic of EC2 mutant strains. A cohort of children with MP-ITP or non-MP ITP admitted to Beijing Children's Hospital from October 2023 to February 2024 was enrolled. Twelve-month outcomes included baseline platelet counts, bleeding severity, short-term responses (at 1 week/1 month/3 months), and sustained remission rates at 6/12 months. The MP group (n = 20, median age 6.4 years) showed lower baseline platelet counts (12.0 × 10⁹/L) and higher proportions of severe bleeding (grade 3/4: 30%) compared with non-MP controls (n = 46, median age 5.5 years; platelets 21.0 × 10⁹/L; grade 3/4: 13%). Following monotherapy/combination therapy, A one-way analysis of covariance(ANCOVA) revealed significantly higher platelet counts in MP-ITP at 3-12 months (p ≤ 0.008), with consistently higher complete response rates in MP-ITP (100% at 1 month, 90% at 12 months) than in non-MP controls (87% at 1 month, 78% at 12 months). In conclusion, MP-related ITP was characterized by severe bleeding but demonstrated favorable treatment responses and long-term outcomes, warranting further investigation of its immunopathogenic mechanisms.
Insights
The macrolide-resistant Mycoplasma pneumoniae (MP) EC2 mutant caused severe bleeding in children with immune thrombocytopenia (ITP). However, MP-related ITP patients showed better treatment responses and long-term outcomes compared to non-MP ITP cases.
Area of Science:
- Pediatrics
- Infectious Diseases
- Hematology
Background:
- Macrolide-resistant Mycoplasma pneumoniae (MP) EC2 mutant emerged as the dominant strain in the 2023-2024 epidemic.
- This strain is linked to immune-mediated complications, including severe immune thrombocytopenia (ITP), with undefined clinical characteristics and prognosis.
- Understanding MP-related ITP is crucial given its association with severe bleeding and potential immune complications.
Purpose of the Study:
- To compare bleeding severity, treatment response, and long-term prognosis in children with MP-associated ITP versus non-MP ITP.
- To analyze outcomes in children diagnosed with severe ITP during the EC2 mutant strain epidemic.
- To investigate the clinical characteristics and prognosis of MP-related ITP in pediatric patients.
Main Methods:
- A cohort study enrolled children with MP-ITP or non-MP ITP at Beijing Children's Hospital (October 2023 - February 2024).
- Evaluated 12-month outcomes including baseline platelet counts, bleeding severity (grade 3/4), short-term responses (1 week, 1 month, 3 months), and sustained remission rates (6, 12 months).
- Utilized one-way ANCOVA to compare platelet counts and response rates between MP-ITP and non-MP ITP groups.
Main Results:
- The MP group (n=20) presented with lower baseline platelet counts (12.0 × 10⁹/L) and higher severe bleeding rates (30%) compared to non-MP controls (n=46, 13%).
- MP-ITP patients showed significantly higher platelet counts at 3-12 months post-treatment (p ≤ 0.008).
- Complete response rates were consistently higher in MP-ITP (100% at 1 month, 90% at 12 months) versus non-MP controls (87% at 1 month, 78% at 12 months).
Conclusions:
- Pediatric MP-related ITP is characterized by severe bleeding but demonstrates favorable treatment responses.
- Long-term outcomes for MP-related ITP are positive, suggesting effective management strategies.
- Further research into the immunopathogenic mechanisms of MP-related ITP is warranted to understand these favorable outcomes.
